Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) Institutional Ownership
CUSIP: 61225M102
13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025
Institutions Reporting
159
Shares (Excl. Options)
64,466,392
Price
$15.68
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- GLUE on Nasdaq
- Shares outstanding
- 80,381,753
- Price per share
- $18.36
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 64,466,392
- Total reported value
- $1,010,809,817
- % of total 13F portfolios
- 0.01%
- Share change
- +4,239,395
- Value change
- +$79,664,773
- Number of holders
- 159
- Price from insider filings
- $18.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Investment Quick Answers
What is CUSIP 61225M102?
CUSIP 61225M102 identifies GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 61225M102:
Significant Owners of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| New Enterprise Associates 17, L.P. | 9.7% | $143,153,471 | 7,797,030 | Ali Behbahani | 17 Mar 2026 | |||
| Dimension Capital I, L.P. | 8.7% | +12% | $88,799,995 | +$14,201,407 | 5,663,265 | +19% | Adam Goulburn | 31 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.5% | $34,360,615 | 4,637,060 | T. Rowe Price Associates, Inc. | 30 Sep 2025 | |||
| TCG Crossover GP II, LLC | 7.2% | $32,812,836 | 4,427,705 | Chen Yu | 10 Oct 2025 | |||
| BAKER BROS. ADVISORS LP | 6.7% | $104,254,207 | 4,345,736 | Baker Bros. Advisors LP | 31 Dec 2025 | |||
| BlackRock, Inc. | 6.3% | $20,045,661 | 3,840,165 | BlackRock, Inc. | 31 Dec 2024 | |||
| BIOTECHNOLOGY VALUE FUND L P | 5.9% | -37% | $92,022,905 | -$43,763,662 | 3,835,886 | -32% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5.5% | $17,539,200 | 3,360,000 | SUVRETTA CAPITAL MANAGEMENT, LLC | 09 Apr 2025 | |||
| VANGUARD GROUP INC | 4.8% | -6% | $22,148,142 | -$1,240,441 | 2,988,953 | -5.3% | The Vanguard Group | 30 Sep 2025 |
| Versant Venture Capital VI, L.P. | 3.4% | -34% | $35,080,976 | -$17,220,640 | 2,236,708 | -33% | Versant Venture Capital VI, L.P. | 07 Jan 2026 |
| FMR LLC | 2.8% | $7,072,953 | 1,750,731 | FMR LLC | 30 May 2025 |
As of 31 Dec 2025, 159 institutional investors reported holding 64,466,392 shares of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE). This represents 80% of the company’s total 80,381,753 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) together control 71% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 9.6% | 7,692,298 | 0% | 6.2% | $120,615,233 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.4% | 5,118,904 | +10% | 0.01% | $80,265,000 |
| TCG Crossover Management, LLC | 5.8% | 4,622,151 | 2.4% | $72,475,328 | |
| Versant Venture Management, LLC | 5.5% | 4,382,687 | -22% | 45% | $68,720,532 |
| BAKER BROS. ADVISORS LP | 5.4% | 4,345,736 | -12% | 0.4% | $68,141,140 |
| BlackRock, Inc. | 5.2% | 4,181,161 | +9.6% | 0% | $65,560,605 |
| BVF INC/IL | 4.8% | 3,835,886 | -32% | 2% | $60,146,692 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.2% | 3,360,000 | 0% | 1.3% | $52,684,800 |
| VANGUARD GROUP INC | 4% | 3,246,500 | +8.6% | 0% | $50,905,120 |
| STATE STREET CORP | 2.6% | 2,107,480 | +149% | 0% | $33,045,286 |
| Aisling Capital Management LP | 1.8% | 1,472,331 | 0% | 4.8% | $23,086,150 |
| AMERICAN CENTURY COMPANIES INC | 1.7% | 1,329,619 | +124% | 0.01% | $20,848,426 |
| FMR LLC | 1.6% | 1,300,096 | -54% | 0% | $20,385,505 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 1,204,844 | +4.6% | 0% | $18,896,352 |
| MPM BIOIMPACT LLC | 1.5% | 1,173,376 | 2.1% | $18,398,536 | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.3% | 1,029,066 | +48% | 2.3% | $16,135,755 |
| BRAIDWELL LP | 1.2% | 948,316 | 0.48% | $14,869,595 | |
| MORGAN STANLEY | 1% | 805,530 | +25% | 0% | $12,630,711 |
| AQR CAPITAL MANAGEMENT LLC | 0.98% | 785,057 | +9.5% | 0.01% | $12,309,694 |
| Vestal Point Capital, LP | 0.96% | 775,000 | -3.1% | 0.45% | $12,152,000 |
| Alphabet Inc. | 0.93% | 744,948 | -49% | 0.45% | $11,680,785 |
| Parkwood LLC | 0.88% | 708,000 | 0% | 0.94% | $11,101,000 |
| NORTHERN TRUST CORP | 0.87% | 697,034 | -5.9% | 0% | $10,929,494 |
| DIMENSIONAL FUND ADVISORS LP | 0.71% | 568,367 | -10% | 0% | $8,913,806 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.65% | 523,377 | +46% | 0.17% | $8,206,551 |
Institutional Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 64,466,392 | $1,010,809,817 | +$79,664,773 | $15.68 | 159 |
| 2025 Q3 | 60,027,627 | $444,802,878 | -$4,386,129 | $7.41 | 126 |
| 2025 Q2 | 62,196,889 | $280,514,086 | +$11,963,150 | $4.51 | 115 |
| 2025 Q1 | 59,523,717 | $276,191,314 | -$11,913,266 | $4.64 | 105 |
| 2024 Q4 | 60,988,332 | $423,262,031 | +$79,110,231 | $6.94 | 104 |
| 2024 Q3 | 49,754,753 | $263,674,421 | +$18,158,687 | $5.30 | 80 |
| 2024 Q2 | 45,836,316 | $171,427,053 | +$21,976,071 | $3.74 | 73 |
| 2024 Q1 | 39,892,581 | $281,249,822 | -$731,896 | $7.05 | 67 |
| 2023 Q4 | 40,102,427 | $226,575,690 | -$10,023,054 | $5.65 | 71 |
| 2023 Q3 | 42,042,126 | $201,382,486 | +$10,940,133 | $4.79 | 70 |
| 2023 Q2 | 39,734,743 | $272,184,520 | -$3,199,539 | $6.85 | 67 |
| 2023 Q1 | 39,769,032 | $309,801,540 | -$11,077,618 | $7.79 | 69 |
| 2022 Q4 | 41,325,746 | $314,458,629 | +$7,213,706 | $7.61 | 66 |
| 2022 Q3 | 40,353,101 | $329,604,037 | -$3,246,200 | $8.17 | 70 |
| 2022 Q2 | 38,778,221 | $374,994,819 | -$11,927,308 | $9.67 | 56 |
| 2022 Q1 | 39,943,480 | $559,876,587 | +$42,034,475 | $14.02 | 52 |
| 2021 Q4 | 36,340,047 | $741,974,000 | +$28,074,571 | $20.42 | 53 |
| 2021 Q3 | 34,892,057 | $759,420,127 | +$60,728,601 | $22.28 | 54 |
| 2021 Q2 | 32,095,195 | $705,074,000 | +$705,074,000 | $22.70 | 48 |